Hugo and colleagues performed exome and transcriptomic sequencing of melanoma pre-treatment samples, and a common gene signature was shown to characterize tumors that were non-responsive to anti-PD-1 therapy[135]. The gene discussed is PDCD1; the disease is melanoma.